Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid Alleviates Tripterygium Glycoside Tablet-Induced Acute Liver Injury by Regulating the Activities of CYP and the Metabolism of Phosphoglycerides
Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute live...
Saved in:
Published in | Frontiers in pharmacology Vol. 12; p. 822154 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
14.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background:
Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated.
Hypothesis/Purpose:
We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites.
Study Design:
TGT-induced acute liver injury models were constructed
in vivo
and
in vitro
. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation.
Methods:
Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin–eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both
in vivo
and
in vitro
.
Results:
Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The
in vitro
results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity.
Conclusion:
This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE. |
---|---|
AbstractList | Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated.Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites.Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation.Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin–eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro.Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity.Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE. Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro . Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin–eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro . Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE. Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. TGT-induced acute liver injury models were constructed and . Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin-eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both and . Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE. Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin-eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro. Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin-eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro. Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE. |
Author | Guo, Qiuyan Li, Min Zhang, Qian He, Xueling Chen, Jiayun Luo, Piao Wang, Qixin Zhong, Tianyu Xia, Fei Zhao, Minghong Lin, Na Xu, Liting Qiu, Chong Zhang, Ying Lu, Tianming Shi, Qiaoli |
AuthorAffiliation | 4 Laboratory Medicine , First Affiliated Hospital of Gannan Medical University , Ganzhou , China 2 China Academy of Chinese Medical Sciences , Beijing , China 3 Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases , Ministry of Education , Gannan Medical University , Ganzhou , China 1 Artemisinin Research Center and Institute of Chinese Materia Medica , China Academy of Chinese Medical Sciences , Beijing , China |
AuthorAffiliation_xml | – name: 2 China Academy of Chinese Medical Sciences , Beijing , China – name: 3 Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases , Ministry of Education , Gannan Medical University , Ganzhou , China – name: 1 Artemisinin Research Center and Institute of Chinese Materia Medica , China Academy of Chinese Medical Sciences , Beijing , China – name: 4 Laboratory Medicine , First Affiliated Hospital of Gannan Medical University , Ganzhou , China |
Author_xml | – sequence: 1 givenname: Qiaoli surname: Shi fullname: Shi, Qiaoli – sequence: 2 givenname: Qixin surname: Wang fullname: Wang, Qixin – sequence: 3 givenname: Jiayun surname: Chen fullname: Chen, Jiayun – sequence: 4 givenname: Fei surname: Xia fullname: Xia, Fei – sequence: 5 givenname: Chong surname: Qiu fullname: Qiu, Chong – sequence: 6 givenname: Min surname: Li fullname: Li, Min – sequence: 7 givenname: Minghong surname: Zhao fullname: Zhao, Minghong – sequence: 8 givenname: Qian surname: Zhang fullname: Zhang, Qian – sequence: 9 givenname: Piao surname: Luo fullname: Luo, Piao – sequence: 10 givenname: Tianming surname: Lu fullname: Lu, Tianming – sequence: 11 givenname: Ying surname: Zhang fullname: Zhang, Ying – sequence: 12 givenname: Liting surname: Xu fullname: Xu, Liting – sequence: 13 givenname: Xueling surname: He fullname: He, Xueling – sequence: 14 givenname: Tianyu surname: Zhong fullname: Zhong, Tianyu – sequence: 15 givenname: Na surname: Lin fullname: Lin, Na – sequence: 16 givenname: Qiuyan surname: Guo fullname: Guo, Qiuyan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35237151$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks2O0zAUhSM0iBmGeQA2yEs2KfFPEocFUikwVCpihMqCleXYTurKiYPtVAovyuvgtB00g4QXdpR77neu7PM8uehtr5LkJcwWGNPqTTPsuFugDMEFRQjm5ElyBYsCpxWF6OLB92Vy4_0-iwtXFS7Is-QS5wiXMIdXye-t470XTg_BdgrwXoKNHrQEX1TgtTW208Kn77lXEnzQXtiDctNbcGsmMTm307-0AEsR9Utj1EHzoDzYzrQoa_XYHZXWa6nAltdGhXTdy1FE2lKMQUWzCATrfj-6CdQT-Kba0fCg-xaEnYqioA866Ei1DVj9uDtOOFfO82nfzZW7nfXDzrbRTLlo5l8kTxtuvLo5n9fJ908ft6vP6ebr7Xq13KSCFHlIC04oFRgKnMcb5KjJSUUaAgUsc44Rl4oTomouGiwJxVJVJS3LClUZwVgWCF8n6xNXWr5ng9MddxOzXLPjD-taxl3QwiiWo0piQeqmrCqCKeFFgyFqZMQVcaOR9e7EGsa6U1KoPjhuHkEfV3q9Y609MEopjvNEwOszwNmfo_KBdfHJlDG8V3b0DBU4JzSrSBalrx56_TW5T0YUlCeBcNZ7pxomdIgPY2drbRjM2BxDdowhm2PITjGMnfCfznv4_3v-AJtp5fA |
CitedBy_id | crossref_primary_10_1002_efd2_70028 crossref_primary_10_1186_s40360_024_00732_y crossref_primary_10_1186_s43066_023_00248_w crossref_primary_10_1016_j_jpha_2023_03_004 crossref_primary_10_1093_toxres_tfae009 crossref_primary_10_1016_j_jff_2024_106390 crossref_primary_10_3390_metabo12111128 crossref_primary_10_3390_microorganisms12061155 crossref_primary_10_3389_fnut_2024_1370975 |
Cites_doi | 10.1124/dmd.116.069419 10.1155/2021/6699560 10.1371/journal.pone.0089450 10.3969/j.issn.1001-5256.2019.08.006 10.1186/s12944-017-0540-4 10.1007/s11010-015-2523-y 10.1016/j.tox.2014.08.013 10.1016/j.phymed.2015.05.053 10.1007/s00216-016-9533-9 10.1016/j.tox.2017.05.012 10.3867/j.issn.1000-3002.2012.03.028 10.7501/j.issn.1674-6376.2017.10.030 10.3760/cma.j.issn.1008-1275.2014.01.001 10.1210/me.2004-0129 10.13193/j.issn.1673-7717.2021.05.017 10.1016/j.phymed.2012.10.013 10.19540/j.cnki.cjcmm.20200710.501 10.1016/j.pharmthera.2013.09.002 10.1007/s00109-011-0771-1 10.2147/DDDT.S220030 10.1016/j.phymed.2019.152855 10.1002/jat.2906 10.7539/j.issn.1672-2981.2017.03.017 10.16438/j.0513-4870.2017-0317 10.19540/j.cnki.cjcmm.20190527.408 10.3390/ijms150915026 10.3390/ijms161125942 10.3969/j.issn.1671-3141.2017.07.016 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo |
Copyright_xml | – notice: Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. – notice: Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fphar.2021.822154 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Shi et al |
EISSN | 1663-9812 |
ExternalDocumentID | oai_doaj_org_article_529d3c4bf7994384a6f312fd7926d798 PMC8883433 35237151 10_3389_fphar_2021_822154 |
Genre | Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c465t-6a488c31c35154a2f5494f41c175a32adea44ebacf3d483de978779290433d623 |
IEDL.DBID | M48 |
ISSN | 1663-9812 |
IngestDate | Wed Aug 27 01:20:38 EDT 2025 Thu Aug 21 13:58:21 EDT 2025 Thu Jul 10 17:47:16 EDT 2025 Thu Jan 02 22:56:31 EST 2025 Tue Jul 01 03:27:52 EDT 2025 Thu Apr 24 23:02:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | tripterygium glycoside tablet liver injury lipid metabolomics glycyrrhizic acid transcriptome |
Language | English |
License | Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c465t-6a488c31c35154a2f5494f41c175a32adea44ebacf3d483de978779290433d623 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology Edited by: Wang Lingzhi, National University of Singapore, Singapore Jinfa Tang, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, China Reviewed by: Chao Han, China Pharmaceutical University, China These authors have contributed equally to this work and share first authorship |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2021.822154 |
PMID | 35237151 |
PQID | 2635480940 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_529d3c4bf7994384a6f312fd7926d798 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8883433 proquest_miscellaneous_2635480940 pubmed_primary_35237151 crossref_citationtrail_10_3389_fphar_2021_822154 crossref_primary_10_3389_fphar_2021_822154 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-02-14 |
PublicationDateYYYYMMDD | 2022-02-14 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in pharmacology |
PublicationTitleAlternate | Front Pharmacol |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Ming (B15) 2017; 16 Wiwi (B23) 2004; 18 Tian (B21) 2019; 44 Liao (B12) 2012; 26 Stingl (B20) 2014; 141 Xie (B25) 2016; 408 Sil (B19) 2015; 409 Graeser (B5) 2011; 89 Ma (B14) 2017; 52 Richard (B17) 2021; 2021 Xia (B24) 2017; 17 Yan (B27) 2016; 44 Luo (B13) 2017; 40 Abuduxikuer (B1) 2019; 35 Gong (B4) 2014; 9 Gu (B6) 2014; 17 Wang (B22) 2017; 386 Kao (B10) 2013; 20 Hsiang (B8) 2015; 22 Na (B16) 2020; 45 Jiang (B9) 2021; 39 Gao (B3) 2019; 13 Xu (B26) 2017; 15 Hou (B7) 2014; 15 Du (B2) 2014; 34 Rudraiah (B18) 2014; 325 Yang (B28) 2019; 58 Li (B11) 2015; 16 |
References_xml | – volume: 44 start-page: 720 year: 2016 ident: B27 article-title: Glycyrrhizin Protects against Acetaminophen-Induced Acute Liver Injury via Alleviating Tumor Necrosis Factor α-Mediated Apoptosis publication-title: Drug Metab. Dispos doi: 10.1124/dmd.116.069419 – volume: 2021 start-page: 6699560 year: 2021 ident: B17 article-title: Exploring the Pivotal Immunomodulatory and Anti-inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids publication-title: Mediators Inflamm. doi: 10.1155/2021/6699560 – volume: 9 start-page: e89450 year: 2014 ident: B4 article-title: Protective Effect of Glycyrrhizin, a Direct HMGB1 Inhibitor, on Focal Cerebral Ischemia/reperfusion-Induced Inflammation, Oxidative Stress, and Apoptosis in Rats publication-title: PloS one doi: 10.1371/journal.pone.0089450 – volume: 35 start-page: 1684 year: 2019 ident: B1 article-title: Congenital Disorders of Glycosylation and Liver Diseases publication-title: J. Clin. Hepatol. = lin chuang gan dan bing za zhi. doi: 10.3969/j.issn.1001-5256.2019.08.006 – volume: 16 start-page: 153 year: 2017 ident: B15 article-title: Liquid Chromatography Mass Spectrometry-Based Profiling of Phosphatidylcholine and Phosphatidylethanolamine in the Plasma and Liver of Acetaminophen-Induced Liver Injured Mice publication-title: Lipids Health Dis. doi: 10.1186/s12944-017-0540-4 – volume: 409 start-page: 177 year: 2015 ident: B19 article-title: Glycyrrhizin Ameliorates Metabolic Syndrome-Induced Liver Damage in Experimental Rat Model publication-title: Mol. Cell Biochem doi: 10.1007/s11010-015-2523-y – volume: 325 start-page: 85 year: 2014 ident: B18 article-title: Differential Fmo3 Gene Expression in Various Liver Injury Models Involving Hepatic Oxidative Stress in Mice publication-title: Toxicology doi: 10.1016/j.tox.2014.08.013 – volume: 22 start-page: 768 year: 2015 ident: B8 article-title: Glycyrrhizin, Silymarin, and Ursodeoxycholic Acid Regulate a Common Hepatoprotective Pathway in HepG2 Cells publication-title: Phytomedicine doi: 10.1016/j.phymed.2015.05.053 – volume: 408 start-page: 4341 year: 2016 ident: B25 article-title: Development and Application of a Comprehensive Lipidomic Analysis to Investigate Tripterygium Wilfordii-Induced Liver Injury publication-title: Anal. Bioanal. Chem. doi: 10.1007/s00216-016-9533-9 – volume: 386 start-page: 133 year: 2017 ident: B22 article-title: Glycyrrhizin and Glycyrrhetinic Acid Inhibits Alpha-Naphthyl Isothiocyanate-Induced Liver Injury and Bile Acid Cycle Disruption publication-title: Toxicology doi: 10.1016/j.tox.2017.05.012 – volume: 26 start-page: 402 year: 2012 ident: B12 article-title: Application Progress of Cytochrome Oxidase P450 Family in Toxicity Study of Traditional Chinese Medicine publication-title: Chin. J. Pharmacol. Toxicol. = zhong guo yao li xue yu du li xue za zhi. doi: 10.3867/j.issn.1000-3002.2012.03.028 – volume: 40 start-page: 1504 year: 2017 ident: B13 article-title: Research Progress of Hepatotoxicity Mechanism and Attenuation of Tripterygium Wilfordii Glycoside publication-title: Drug Eval. Res. = yao wu ping jia yan jiu. doi: 10.7501/j.issn.1674-6376.2017.10.030 – volume: 17 start-page: 1 year: 2014 ident: B6 article-title: Effect of Glycyrrhizin on Traumatic Brain Injury in Rats and its Mechanism publication-title: Chin. J. Traumatol. doi: 10.3760/cma.j.issn.1008-1275.2014.01.001 – volume: 18 start-page: 1975 year: 2004 ident: B23 article-title: Sexually Dimorphic P450 Gene Expression in Liver-specific Hepatocyte Nuclear Factor 4alpha-Deficient Mice publication-title: Mol. Endocrinol. doi: 10.1210/me.2004-0129 – volume: 39 start-page: 64 year: 2021 ident: B9 article-title: Research Progress on Adverse Reactions and Reducing Toxicity of Tripterygium Glycosides publication-title: Chin. rchives traditional Chin. Med. = zhong hua zhong yi yao xue kan. doi: 10.13193/j.issn.1673-7717.2021.05.017 – volume: 20 start-page: 295 year: 2013 ident: B10 article-title: Glycyrrhizic Acid and 18β-Glycyrrhetinic Acid Recover Glucocorticoid Resistance via PI3K-Induced AP1, CRE and NFAT Activation publication-title: Phytomedicine doi: 10.1016/j.phymed.2012.10.013 – volume: 45 start-page: 4149 year: 2020 ident: B16 article-title: Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium Wilfordii Tablets in Treatment of Rheumatoid Arthritis publication-title: Zhongguo Zhong Yao Za Zhi doi: 10.19540/j.cnki.cjcmm.20200710.501 – volume: 141 start-page: 92 year: 2014 ident: B20 article-title: Relevance of UDP-Glucuronosyltransferase Polymorphisms for Drug Dosing: A Quantitative Systematic Review publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2013.09.002 – volume: 89 start-page: 1027 year: 2011 ident: B5 article-title: Nrf2-dependent Gene Expression Is Affected by the Proatherogenic apoE4 Genotype-Studies in Targeted Gene Replacement Mice publication-title: J. Mol. Med. (Berl) doi: 10.1007/s00109-011-0771-1 – volume: 13 start-page: 3579 year: 2019 ident: B3 article-title: Diammonium Glycyrrhizinate Mitigates Liver Injury via Inhibiting Proliferation of NKT Cells and Promoting Proliferation of Tregs publication-title: Drug Des. Devel Ther. doi: 10.2147/DDDT.S220030 – volume: 58 start-page: 152855 year: 2019 ident: B28 article-title: Tripterygium Glycoside Fraction N2: Alleviation of DSS-Induced Colitis by Modulating Immune Homeostasis in Mice publication-title: Phytomedicine doi: 10.1016/j.phymed.2019.152855 – volume: 34 start-page: 878 year: 2014 ident: B2 article-title: Metabolic Pathways Leading to Detoxification of Triptolide, a Major Active Component of the Herbal Medicine Tripterygium Wilfordii publication-title: J. Appl. Toxicol. doi: 10.1002/jat.2906 – volume: 15 start-page: 329 year: 2017 ident: B26 article-title: Effect of Licorice on Drug Metabolism Enzymes and In Vivo Metabolism of Chemical Agents publication-title: Cent. south Pharm. = zhong nan yao xue doi: 10.7539/j.issn.1672-2981.2017.03.017 – volume: 52 start-page: 1077 year: 2017 ident: B14 article-title: Study of Metabolic Pathway of Radix glycyrrhiza in Decreasing Liver Toxicity of Tripterygium Wilfordii publication-title: Acta pharmaceutica sinica = yao xue xue bao doi: 10.16438/j.0513-4870.2017-0317 – volume: 44 start-page: 3399 year: 2019 ident: B21 article-title: Overview of Hepatotoxicity Studies on Tripterygium Wilfordii in Recent 20 Years publication-title: Zhongguo Zhong Yao Za Zhi doi: 10.19540/j.cnki.cjcmm.20190527.408 – volume: 15 start-page: 15026 year: 2014 ident: B7 article-title: The Protective Effect of Glycyrrhizic Acid on Renal Tubular Epithelial Cell Injury Induced by High Glucose publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms150915026 – volume: 16 start-page: 26087 year: 2015 ident: B11 article-title: The Role of Oxidative Stress and Antioxidants in Liver Diseases publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms161125942 – volume: 17 start-page: 33 year: 2017 ident: B24 article-title: Research Progress of Drug-Induced Liver Injury publication-title: World latest Med. Inf. = shi jie zui xin yi xue xin xi wen zhai doi: 10.3969/j.issn.1671-3141.2017.07.016 |
SSID | ssj0000399364 |
Score | 2.3868873 |
Snippet | Background:
Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium... Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet... Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 822154 |
SubjectTerms | glycyrrhizic acid lipid metabolomics liver injury Pharmacology transcriptome tripterygium glycoside tablet |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQT70goHyEQjVIqAfUUBI7X71tC6UgFa3QViqnyLGdTdBustpkD-kf7d9hxkm3uwjBhcse1hPbip89bxTPG8beYmicoJcLXaORvoks13gOauWKhNTLDA-ykJKTL7-FF1fi63VwvVHqi-6E9fLA_Ys7DvxEc4WdREkieCxkmHPPz3WU-CH-2DRf9HkbwZQ9g8nvhqL_jIlRWHKcLwpJ-p--9x59oheILUdk9fr_RDJ_vyu54XzOH7GHA2uEUT_bx-yBqZ6ww3EvO90dweQ-i6o5gkMY3wtSd3vs1jokezzUcwOy0kAlqzVcmhYxMKPE5MY9RX-m4WPZKLrV2Z3A51mnuuWyKG9KBSOF9qMZJaMTO4UJ9YZm03I1t5Y11f2ECWVitS4VBFHY20itWoODYYfwpfqJ6wdZB9_N1BYNq6aA9BONbAULDNmhzuHsx9jOkFqG-ZXNnFrGRd0sinqKg-G20aZ5yq7OP03OLtyhoIOrRBi0bijxuFDcUxxZlJB-jsGpyIWnkMNI7kttpBAmkyrnWsRcGwxxI1zohFTWNBK1Z2ynqivzgoH2RBDLKMtwYYSKMykjjN106Ek_igI_cNiHu9VN1aB2TkU3ZilGPQSI1AIiJUCkPSAc9m79yKKX-vib8SlBZm1IKt32D8RuOmA3_Rd2HfbmDnAp7mr6VCMrU6-alCSCREzahg573gNwPRRSZh4hUXNYtAXNrblst1RlYZXD4zjm-Cpf_o_J77Ndn1JBqDiOeMV22uXKvEaC1mYHdi_-AsZHPgs priority: 102 providerName: Directory of Open Access Journals |
Title | Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid Alleviates Tripterygium Glycoside Tablet-Induced Acute Liver Injury by Regulating the Activities of CYP and the Metabolism of Phosphoglycerides |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35237151 https://www.proquest.com/docview/2635480940 https://pubmed.ncbi.nlm.nih.gov/PMC8883433 https://doaj.org/article/529d3c4bf7994384a6f312fd7926d798 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWRUJ7QbwJj5WR0B7QZiGx80JCqLuwLEhFFWql5RQ5tvNAbVKSVCL8Uf4OM07apajiwCWHePxoPOP5psl8Q8hzCI0j8HK-rRXAN56kCs5BJW0eIXuZZl7iY3Ly-LN_MeOfLr3LPbIubzU8wGZnaIf1pGb1_OTH9-4tGPwbjDjB375Ml7lAak_XOQF3B5jgGrkOjilAOx0PaN8czOiMfd6_29zd84DcAETCAsdzthyV4fPfBUL__pbyD-d0fovcHFAlHfVqcJvs6fIOOZr0tNTdMZ1eZVk1x_SITq4Iq7u75JdxWOb4qBaailJRLGmt6Fi3oCNzTFxu7FPwd4q-KxqJX312r-mHeSe7us6Ln4WkIwnyozkmqyN6pVMcDcSyYrUwkhXWBaVTzNRqbSwYImG0kVy1GiaDAenH8hvsL006-kVnpqhYmVGApyBkKlxASE-rlJ59nZgVYsuwvqJZYMskr5plXmUwGZiV0s09Mjt_Pz27sIeCD7bkvtfavoDjRDJHMkBZXLgpBK885Y4EjCOYK5QWnOtEyJQpHjKlIQQOAgB4yMKmAMjdJ_tlVeqHhCqHe6EIkgQ2hsswESKA2E75jnCDwHM9i7xa724sBzZ0LMoxjyEqQt2IjW7EqBtxrxsWebHpsuypQP4lfIoqsxFEFm9zo6qzeDgUYs-NFJNgIEEUcRZy4afMcVMFP8mHS2iRZ2uFi8Hq8VWOKHW1amKkEOIhch9a5EGvgJup1gpskWBLNbfWst1SFrlhFg_DkMGjfPTfPR-TAxfzQ7BiDn9C9tt6pZ8CamuTQ_Nvx6GxyN-XyEhp |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transcriptome+and+Lipid+Metabolomics-Based+Discovery%3A+Glycyrrhizic+Acid+Alleviates+Tripterygium+Glycoside+Tablet-Induced+Acute+Liver+Injury+by+Regulating+the+Activities+of+CYP+and+the+Metabolism+of+Phosphoglycerides&rft.jtitle=Frontiers+in+pharmacology&rft.au=Shi%2C+Qiaoli&rft.au=Wang%2C+Qixin&rft.au=Chen%2C+Jiayun&rft.au=Xia%2C+Fei&rft.date=2022-02-14&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=12&rft_id=info:doi/10.3389%2Ffphar.2021.822154&rft_id=info%3Apmid%2F35237151&rft.externalDocID=PMC8883433 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |